a team dedicated to gastroenterology-focused technologies

giiant pharma Inc is a Montreal-based biotech company, founded by two former Merck Frosst scientists, and repeat entrepreneurs with a significant depth of expertise in the area of Gastrointestinal drug development. Guided by the concept of Precision Delivery and using its proprietary GastroIntestinal-Induced ANti-inflammatory Technology (GIIANT) the company has developed its lead program GT-2108 for the treatment of moderate-to-severe ulcerative colitis. This approach capitalizes on the enzymatic activity of the colon microbiota to bioactivate the prodrug of phosphodiestherase-4 (PDE4) inhibitor and specifically release the active moiety at the site of inflammation.

Leadership

Maxime RangerPhD, MBA

Executive Chairman

Since January 2022, Maxime has been appointed as Executive Chairman of Giiant Pharma, after more than 2 years as CEO. As a serial entrepreneur, Maxime played a leading role in the creation and management of Mperia therapeutics, Inversago Pharma, SemaThera and Neurasic Therapeutics, to name a few.

Christophe MellonPhD

Chief Executive Officer

After synthetic organic chemistry training at Université de Montréal and a post-doc at MIT, Christophe benefited from the large number of opportunities offered to innovative medicinal chemists at Merck Frosst. His entrepreneurial spirit let him to contribute significantly to the initial tools necessary to start two medicinal chemistry programs.

more about Christophe

Patrick ColinB.Pharm, PhD

Chief Clinical Officer

Bringing more than 33 years of experience in various corporate environments, encompassing large multinational firms, growing biopharmaceutical companies and biotechs/start-ups, Patrick is an expert in gastroenterology and hepatology preclinical and clinical drug development (Phases 1 to 4).

more about patrick

Micheline BeauvaisCPA, MBA

Acting CFO

Micheline brings key financial expertise to giiant, acquired throughout her career in the banking industry, as well as during her tenure as Chief Financial Officer (CFO) at Locus Dialogue Inc. Since 2002, Micheline has been working as part-time CFO for small, venture-backed, technology start-up companies. Her expertise is well recognized throughout the biotech industry (she has 20+ biopharmaceutical companies in her professional portfolio).

more about micheline

Board of Directors

Jamie Stiff

Managing Director

Genesys Capital

Véronique Missout

Investment Manager

Fonds FTQ

Patricia Escoffier

Principal

Theodorus

Jesse Paterson

AQC/CQDM joint seat

Maxime Ranger

CEO

Giiant Pharma

Investors

Genesys Capital is one of the largest Canadian- based venture capital firms exclusively focused on the life sciences industry. Genesys is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys Capital accelerates the development of commercially viable emerging companies that represent promising life sciences investment opportunities.

genesyscapital.com

The Fonds de solidarité FTQ is investing in a better society thanks to its over 700,000 shareholder-savers. Through its private equity and venture capital investments, the Fonds seeks to have a positive impact on society, namely in the health, environmental and innovation sectors. With net assets of $15.6 billion as at November 30, 2020, the Fonds supported over 3,300 partner companies and more than 220,000 jobs.

fondsftq.com

AmorChem is a leading early-stage venture fund dedicated to creating the next generation of biotech companies from academic research. Since 2011, with $87 million under management, AmorChem has financed over 33 research programs in academia and accelerated the spin-off and creation of several biotech companies, each with its own ground-breaking therapeutic paradigm. Overall it has led to ten startup companies where AmorChem played a role as founding investor.

amorchem.com

Founded in 2010, Crystal Pharmatech is a technology-driven contract research organization, providing comprehensive solutions in solid-state research, crystallization development, pre-formulation studies and formulation development to large pharma corporations and biotech companies. Based in Suzhou (China), New Jersey (USA) and Toronto (Canada), the company has supported the solid-state research and pre-formulation studies of more than 1500 compounds for over 800 clients from USA and China.

crystalpharmatech.com

AQC Capital is an early-stage Venture Capital fund with over 150 M$ in assets under management to support Quebec’s start-up ecosystem. Investing alongside successful angels, members of the Anges Québec Network, the AQC Capital team offers active and dynamic support in addition to the capital needed by entrepreneurs to reach new heights. As of today, AQC Capital has invested in 53 innovative companies.

aqccapital.ca

CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Quebec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned.

cqdm.org

Anges Québec is a leader in the Québec early-stage investment ecosystem. To date, its 230 Angel Investors have invested more than $117 million in the Québec economy, counting more than 157 companies in its portfolio.

angesquebec.com